【Key phrases for RM1 and RM2】
注1）「キーフレーズ」をクリックするとライフサイエンス辞書コーパスにジャンプし、「EtoJ」をクリックすると英和辞典にジャンプします。
注2）ライフサイエンス辞書サイトから戻るためには、ブラウザの「戻る」矢印を使ってください。
＜RM1: Describing Research Results＞
＜RM1-Step1: Describing methods＞
RM1-Step1a（Procedure）
a total of * patients were EtoJ
ex. a total of * patients were enrolled EtoJ
were randomly assigned to EtoJ
ex. a total of * patients were randomly assigned to receive EtoJ
ex. participants were randomly assigned to one of
ex. data were available for * patients EtoJ
ex. the median duration of follow-up was * months EtoJ
ex. the most common reason for discontinuation EtoJ
＜RM1-Step2: Indicating specific observations＞
RM1-Step2a（Presentation of results）
Table 1 shows EtoJ
ex. Table 1 shows the characteristics of EtoJ
ex. are shown in Table 1
ex. are presented in Table 1
the baseline characteristics of EtoJ
the baseline characteristics of the patients EtoJ
ex. Table 1 shows the baseline characteristics of EtoJ
RM1-Step2b（Findings）
ex. we found that EtoJ
ex. we noted a significant EtoJ
ex. responses were observed in EtoJ
ex. median progression-free survival was * months EtoJ
RM1-Step2c（Possibility）
＜RM1-Step3: Indicating comparison or changes＞
RM1-Step3a（Comparison）
ex. was associated with a lower risk of EtoJ
significantly associated with EtoJ
ex. there was a significant difference EtoJ
ex. there was a significant interaction between EtoJ
ex. higher in the * group than in the EtoJ
as compared with patients EtoJ
RM1-Step3b（Changes）
ex. associated with a significant increase in EtoJ
ex. increased significantly in the cohort EtoJ
ex. had a significantly increased risk EtoJ
ex. was/were significantly increased EtoJ
RM1-Step3c（Similarity）
were similar in the two groups EtoJ
characteristics were similar in EtoJ
was similar between groups EtoJ
ex. were well balanced between EtoJ
baseline characteristics were EtoJ
ex. baseline characteristics were similar between EtoJ
ex. baseline characteristics were well balanced between EtoJ
RM1-Step3d（No difference）
did not differ significantly EtoJ
did not differ significantly between
ex. difference was not significant EtoJ
there was no significant difference EtoJ
there were no significant differences EtoJ
ex. did not change substantially EtoJ
＜RM2: Describing Adverse Events＞
＜RM2-Step1: Describing adverse events＞
RM2-Step1a（Adverse events）
the most common adverse events EtoJ
ex. the most common adverse events were fatigue, EtoJ
the incidence of adverse events EtoJ
ex. the incidence of adverse events was similar in the two groups EtoJ
rate of serious adverse events EtoJ
serious adverse events occurred in * patients EtoJ
adverse events were reported in * patients EtoJ
had a serious adverse event EtoJ
ex. patients had a serious adverse event EtoJ
one or more serious adverse EtoJ
ex. participants had one or more serious adverse event
adverse events related to EtoJ
ex. adverse events are summarized in Table 1
limit of the normal range EtoJ
ex. times the upper limit of the normal range EtoJ
RM2-Step1b（No adverse events）
no serious adverse events EtoJ
ex. no serious adverse events were reported EtoJ
did not differ significantly between EtoJ
ex. rate of serious adverse events did not differ significantly between
there were no significant differences EtoJ
ex. we noted no significant difference between EtoJ
＜RM2-Step2: Indicating discontinuation＞
RM2-Step2a（Discontinuation）
discontinuation of the study drug EtoJ
ex. led to discontinuation of the study drug EtoJ
discontinued the study drug EtoJ
ex. patient discontinued the study drug EtoJ